



T.F.W.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla, *et al.*

Confirmation No.: 9201

Serial No.: 10/609,298

Art Unit: 1623

Filed: June 27, 2003

Examiner: Travis C. McIntosh III

For: 2' AND 3' NUCLEOSIDE
PRODRUGS FOR TREATING
FLAVIVIRIDAE INFECTIONSAttorney Docket No.: 11874-016-999
(417451-999016)

IDX 1017

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicant.

Copies of References B01 to B77 and C01 to C146 are submitted herewith. References A01 to A91 are U.S. patents and U.S. published applications. Therefore, copies of these references are not submitted herewith, pursuant to 37 C.F.R. § 1.98(a)(2)(ii). References A92 to A95 are pending unpublished U.S. patent applications. Therefore, copies of the specification, claims and drawings for each are submitted herewith, pursuant to 37 C.F.R. § 1.98(a)(2)(iii).

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application. Identification of references listed on PTO Form 1449 is not to be construed as an admission of Applicants or attorneys for Applicants that such references are available as "prior art" against the subject application.

Respectfully submitted,

Date: July 20, 2007

Dale L. Rieger

Reg. No. 43,045

JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1200